

Acquired mutations in patients with relapsed/refractory chronic lymphocytic leukemia that progressed in the ALPINE study

Authors: Renata Walewska,¹ Jessica Li,² Barbara F. Eichhorst,³ Nicole Lamanna,⁴ Susan M. O'Brien,⁵ Constantine S. Tam,⁶ Luqui Qiu,⁷ Tommi Salmi,⁸ Mazyar Shadman⁹ Jennifer R. Brown,¹⁰

Affiliations: ¹Department of Haematology, University Hospitals Dorset, Bournemouth, UK; ²BeiGene USA, Inc, San Mateo, CA, USA; ³Department of Internal Medicine, University of Cologne, Center for Integrated Oncology Aachen Bonn Köln Düsseldorf, Cologne, Germany; ⁴Columbia University, New York, NY, USA; ⁵University of California, Irvine, Irvine, CA; ⁶Alfred Hospital and Monash University, Melbourne, VIC, Australia; ⁷Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, China; ⁸BeiGene International GmbH, Basel, Switzerland; ⁹Fred Hutchinson Cancer Center, University of Washington School of Medicine, Seattle, WA, USA; ¹⁰Dana-Farber Cancer Institute, Boston, MA, USA;

ABSTRACT

Introduction: Patients receiving covalent Bruton tyrosine kinase inhibitors (cBTKis) for chronic lymphocytic leukemia (CLL) can develop drug resistance, leading to progressive disease (PD). cBTKi binding site mutations (C481) are most common. For insights into cBTKi resistance in a randomized CLL patient population, we performed next-generation sequencing (NGS) on samples from patients who progressed on zanubrutinib or ibrutinib in the phase 3 ALPINE study (NCT03734016).

Patients and methods: PD (Hallek et al. *Blood*. 2008) was determined by independent review (n=139) and/or investigator (n=132); 57 patients (zanubrutinib, n=26; ibrutinib, n=31) had PD samples (median follow-up: zanubrutinib, 25.4 months; ibrutinib, 28.1 months). Paired blood samples from baseline and at or after PD and prior to subsequent therapy from patients without Richter transformation at PD were included (zanubrutinib, n=24; ibrutinib, n=28). A 106-gene NGS panel, including putative CLL driver genes, was used (*BTK* and *PLCG2* mutations, variant allele frequency [VAF] $\geq 0.25\%$; all other genes: pathogenic mutations, VAF $\geq 1\%$). Baseline chromosome abnormalities were assessed.

Results: No baseline *BTK* mutations were detected. Nine patients acquired *BTK/PLCG2* mutations: 8 in *BTK* (zanubrutinib, n=5; ibrutinib, n=3); 2 in *PLCG2* (both ibrutinib; 1 in both *BTK* and *PLCG2*). Of 18 *BTK* single-nucleotide variants (SNVs), 77.8% (zanubrutinib, n=11; ibrutinib, n=3) were at C481; 3/24 zanubrutinib patients had non-C481 *BTK* mutations. Median treatment duration at PD was shorter in patients without (zanubrutinib: n=19, 16.8 months; ibrutinib: n=25; 15.9 months) vs with (zanubrutinib: n=5; 29.7 months; ibrutinib: n=3; 30.8 months) acquired *BTK* mutations. Baseline mutations in 18/27 driver genes were observed in 48/52 patients; most frequent: *NOTCH1* (n=21), *TP53* (n=19), *BRAF* (n=10), *SF3B1* (n=8), and *ATM* (n=8). Twenty-three patients had copy number aberrations (CNAs) in 9/27 driver genes; most frequent: *CCND2* (n=10), *ATM* (n=8), *TP53* (n=6), and *KMT2D* (n=6). At PD, 6 patients acquired SNVs (zanubrutinib: *TP53* and *XPO1* in n=1; ibrutinib: *TP53*, *SETD2*, *SF3B1* [each n=1], *ASXL1* in n=2). Ten patients acquired CNAs in driver genes (most frequent: *KRAS* [zanubrutinib, n=3]; *NRAS* [ibrutinib, n=2]; *CDKN1B* [zanubrutinib, n=2; ibrutinib, n=1]; *BIRC3* [ibrutinib, n=2]). Acquired driver gene mutations were not associated with del(17p), IGHV mutation, or complex karyotype status.

Conclusion: Of 52 patients, most (82.6%) did not acquire *BTK/PLCG2* mutations. These data suggest *BTK* and/or *PLCG2* mutations are not the sole factors driving PD in this population. Given the low incidence of non-C481 mutations in patients with PD in ALPINE, patients with CLL treated with cBTKis likely remain sensitive to other BTK-targeting therapies.